FAM210B Antibody - BSA Free

Immunohistochemistry-Paraffin: FAM210B Antibody [NBP2-14523] - Staining of human prostate shows strong cytoplasmic positivity in glandular cells.

Immunohistochemistry-Paraffin: FAM210B Antibody [NBP2-14523] -Staining of human fallopian tube shows strong granular cytoplasmic positivity in glandular cells.

Immunohistochemistry-Paraffin: FAM210B Antibody [NBP2-14523] -Staining of human liver shows strong granular cytoplasmic positivity in hepatocytes.

Immunohistochemistry-Paraffin: FAM210B Antibody [NBP2-14523] -Staining of human kidney shows strong granular cytoplasmic positivity in cells in tubules.

FAM210B was frequently downregulated in HCC. (A) The FAM210B levels were determined in 64 HCC and paired non−tumor paraffin samples by immunohistochemistry (IHC) assays. (B) The levels of FAM210B in HCC and adjoining non-tumor tissues were evaluated by IHC staining (n = 64). (C) IHC staining photos demonstrating FAM210B expression in HCC tumor and adjoining non-tumor samples (scale bar = 400 μm). (D) The overall survival of 64 individuals with HCC–related FAM210B expression was evaluated via the Kaplan–Meier method. p Values were derived through the log-rank test. (E) The levels of FAM210B mRNA were detected in HCC cells and in the hepatic immortal cell line HL02 by qRT−PCR assays. (F) The levels of FAM210B protein were detected by Western blot assays in the HCC cells and hepatic immortal cell line HL02. Quantitative analysis of Western blot is shown. *: p < 0.05; ***, p < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37189851), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

FAM210B suppressed the migration and invasion of LUAD cells in vitro and the tumor metastasis of LUAD tumor in vivo.A, B Transwell assays were conducted to analyze the migration and invasion abilities of H1299 cells or A549 cells transiently (left) or stably (right) overexpressing FAM210B (upper). The quantitative analysis of invasion and migration in H1299 and A549 cells was shown in the lower panels. **P < 0.01, ***P < 0.001 (Student’s t-test). C Transwell assays were performed in FAM210B knocked-down H1299 cells (left). The quantitative analysis of invasion and migration in left panel was shown in the right panel. **P < 0.01, ***P < 0.001 (Student’s t-test). D, E Western blot was performed on H1299 and A549 cells transiently transfected with GFP-FAM210B or FAM210B siRNA to analyze the expression of EMT markers. F Wound healing experiments were conducted on H1299 cells transiently overexpressing GFP-FAM210B and on A549 cells stably overexpressing FAM210B. The quantitative analysis of the scratch width was presented below the corresponding images (mean +/- SEM, n = 3). *P < 0.05 (Student’s t-test). G Representative bioluminescent images of NCG mice acquired 40 days after tail intravenous injection of A549 cells expressing OE-V-Luc or OE-FAM210B-Luc. H Pictures of lungs taken from the indicated groups of nude mice (left), and histological examination of lung tissues using HE staining (right). Scale bar: 100 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/39900908), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

FAM210B expression level was positively correlated with overall survival in LUAD patients.Kaplan-Meier survival analysis of the relationship between FAM210B expression and overall survival in TCGA-LUAD RNA-seq data (A), GSE30219 (B), and GSE31210 (C), with high expression of FAM210B denoted in red and low expression of FAM210B in black. D qRT-PCR was used to analyze the expression levels of FAM210B gene in HBE, H1299, and A549 cell lines. E Western blot analysis of FAM210B protein expression in HBE, H1299, and A549 cell lines (Upper). Quantitative analysis of FAM210B protein expression of three independent repeated experiments (Lower). Data of D-E were represented as mean +/- SEM of three independent experiments. Statistical analysis was performed using Student’s t-test. ***P < 0.001, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/39900908), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

FAM210B activated the IFN-alpha / beta mediated STAT1/IRF9/IFIT3 signal pathway.A GO Biological Process (BP) analysis of 113 DEGs regulated by FAM210B, with the top 15 BPs listed. B A schematic representation of the type I IFN signaling pathway. The circled P represents phosphate. C Log (fold change) of mRNA expression level of DEGs involved in the type I IFN signaling pathway, as assayed by RNA-seq with FAM210B overexpressing or knockdown H1299 cells. All the selected genes have a P value of less than 0.01 (**P < 0.01). qRT-PCR assays were used to test the expression levels of several representative members of the type I IFN signaling pathway, along with IFN-alpha and IFN-beta , in H1299 cells overexpressing GFP-FAM210B (D) or following FAM210B knockdown (E) (mean +/- SEM, n = 3). F Western blotting was conducted in H1299 cells with FAM210B knockdown or overexpression (OE-FAM210B) to evaluate changes in representative members of the type I IFN signaling pathway. G–H qRT-PCR assays were employed to assess the expression levels of STAT1, IRF9, and IFIT3 in LUAD cells under treatment with IFN-alpha or IFN-beta at different time points (n = 2), respectively. Statistical analysis was performed using Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/39900908), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Loss of FAM210B promotes HCC cell metastasis in vitro. (A) The transwell migration assay was conducted in Hep3B and HepG2 cells following transfection with FAM210B shRNA lentivirus or FAM210B overexpression lentivirus. (Scale bar = 200 μm). (B) Statistical graphs of cell transmembrane numbers of the two groups. (C) Stable downregulation of FAM210B expression increased the invasive potential of Hep3B and HepG2 cells in vitro as per Matrigel chamber experiments, but upregulation of FAM210B decreased invasiveness. (Scale bar = 400 μm). (D) Statistical graphs of cell transmembrane number in the two groups. *: p < 0.05; **, p < 0.01; ***, p < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37189851), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Loss of FAM210B promotes HCC cell metastasis in vitro. (A) The transwell migration assay was conducted in Hep3B and HepG2 cells following transfection with FAM210B shRNA lentivirus or FAM210B overexpression lentivirus. (Scale bar = 200 μm). (B) Statistical graphs of cell transmembrane numbers of the two groups. (C) Stable downregulation of FAM210B expression increased the invasive potential of Hep3B and HepG2 cells in vitro as per Matrigel chamber experiments, but upregulation of FAM210B decreased invasiveness. (Scale bar = 400 μm). (D) Statistical graphs of cell transmembrane number in the two groups. *: p < 0.05; **, p < 0.01; ***, p < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37189851), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

FAM210B inhibited HCC cell growth in vitro. (A) CCK-8 assays were used to assess the FAM210B-deficient Hep3B and HepG2 cell viability once a day for 4 days. (B) Overexpression of FAM210B in Hep3B and HepG2 cells inhibited cell growth, as shown by CCK-8 assays. (C) Clonal expansion analysis was conducted in FAM210B-deficient Hep3B and HepG2 cells. (D) The effects of FAM210B overexpression on the survival cells were examined using colony formation assays. When colonies were stained with crystal violet, they appeared purple. (E) The impacts of FAM210B knockdown on cellular malignant transformation were assessed by soft agar colony formation assay. (Scale bar = 1 mm). (F) The effects of FAM210B overexpression on cellular malignant transformation were assessed by soft agar colony formation assay. *: p < 0.05; **, p < 0.01; ***, p < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37189851), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu
• Applications: IHC
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free

FAM210B Antibody - BSA Free Summary

• Immunogen: This antibody was developed against Recombinant Protein corresponding to amino acids: RLDARLLRTARGDCRGHQDPSQATGTTGSSVSCTEEKKQSKSQQLK
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: FAM210B
• Purity: Affinity purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 1:200 - 1:500
  • Immunohistochemistry-Paraffin 1:200 - 1:500
• Application Notes: For IHC-Paraffin, HIER pH 6 retrieval is recommended.
• Control Peptide:

  FAM210B Protein (NBP2-14523PEP)

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.2) and 40% Glycerol
• Preservative: 0.02% Sodium Azide
• Purity: Affinity purified

Alternate Names for FAM210B Antibody - BSA Free

• 5A3
• C20orf108
• dJ1167H4.1
• FAM210B family with sequence similarity 210, member B

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FAM210B Antibody (NBP2-14523)(1)

Publication using NBP2-14523

• Zhou, Y;Pan, X;Liu, Y;Li, X;Lin, K;Zhu, J;Zhan, L;Kan, C;Zheng, H; Loss of the Novel Mitochondrial Membrane Protein FAM210B Is Associated with Hepatocellular Carcinoma Biomedicines 2023-04-21 [PMID: 37189851] (Immunohistochemistry, Western Blot, Human)

Bioinformatics

• Gene Symbol: FAM210B